In large cardiovascular outcome trials and studies in people with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), SGLT2 inhibitors reduced heart failure symptoms as well as heart failure hospitalizations and cardiovascular death [2, 3, 4]. This evidence concerns the gene SLC5A2 and heart failure.